Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2020

Disaggregation of Revenue

Revenue for the years ended December 31, 2020, 2019 and 2018 was as follows (amounts in thousands, except percentages):

	For the Years Ended December 31,
	2020		2019		2018
	(Amounts in thousands)
Product revenue	$	366,136	$	270,097	$	193,891
Royalty and other income		124		148		141
Total revenue	$	366,260	$	270,245	$	194,032

Revenue from Significant Customers

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows (amounts in thousands):

	For the Years Ended December 31,
	2020		2019		2018
MilliporeSigma	$	39,511	$	36,190	$	29,843
Cytiva (formerly GE Healthcare)		N/A	$	31,441	$	29,616

Summary of Receivables and Deferred Revenue from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of December 31, 2020 (amounts in thousands):

	2020		2019
Balances from contracts with customers only:
Accounts receivable	$	71,257	$	43,068
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	$	15,318	$	5,005
Revenue recognized during years presented relating to:
The beginning deferred revenue balance	$	3,361	$	833
Changes in pricing related to products or services satisfied in previous periods		—		—